



For Immediate Release
Bill Wells – 404-281-7490

Dr. Alexander Fleming Named to DiaKine Therapeutics’ Scientific Advisory Board

Dr. Fleming is an internationally recognized thought leader in diabetes

CHARLOTTESVILLE, VA (May 15, 2007) -- DiaKine Therapeutics, Inc., a developer of drugs designed to treat diabetes and other immune-related diseases via a novel approach, today announced the appointment of Dr. Alexander “Zan” Fleming to its Scientific Advisory Board.

Dr. Fleming is a well recognized authority in the metabolic and endocrine fields with extensive U.S. Food and Drug Administration (FDA) experience. He served 12 years as FDA Supervisory Medical Officer for diabetes and other metabolic and endocrine disorders and held assignments with World Health Organization (WHO) and the International Conference on Harmonization (ICH). He led reviews and was responsible for the regulation of the earliest biotech products as well as all diabetes therapies approved during the 1990’s. Soon after arriving at FDA from NIH, he was responsible for the review and approval of the first statin.

“I am honored be associated with the work that Dr. Jerry Nadler and his team are doing at DiaKine,” said Dr. Fleming. “I believe that the drugs being developed by DiaKine have the potential to play a major role in definitive treatments or cures for diabetes. DiaKine’s mechanistic approaches are unique among diabetes therapies under development. DiaKine’s drugs have great promise for not only working alone but synergistically with both immunomodulatory and islet regenerative therapies.”

“Dr. Fleming brings a wealth of experience and expertise in diabetes, regulatory affairs and business development to our efforts, and I look forward to our working relationship,” said Dr. Nadler, DiaKine’s Chief Scientific Officer.

“I am pleased to welcome Dr. Fleming to our Scientific Advisory Board, and believe that his unique understanding of diabetes will be invaluable as we work to bring our therapies to market,” said Keith Ignatz, President, and CEO of DiaKine.

###MORE###

Dr. Fleming is President and Chief Executive Officer of Kinexum: an incubator organization for advancing innovative ideas, healthcare products, and services directed towards meeting important unmet clinical needs. At FDA, he also chaired the professional education and training for FDA's Center for Drug Evaluation & Research and was a major contributor to FDA's Good Review Practice initiative. He is frequent invited lecturer at international symposia and has served as an invited editorialist of the *New England Journal of Medicine* and other publications. Dr. Fleming joins Dr. Mark Atkinson, an internationally recognized authority on multiple aspects pertaining to type 1 diabetes, and Dr. Raghu Mirmira, a leading authority on beta cell development and function and the study of the regulation of insulin gene expression, on the DiaKine Scientific Advisory Board.

Drugs being developed by Diakine modulate cytokines, part of the body's immune system, which sometimes mistakenly attack normal organs and tissue and cause diseases such as diabetes and multiple sclerosis. Research by Dr. Nadler and his collaborators published in 2006 showed that controlling certain cytokines can arrest the progression of, or reverse, type 1 diabetes in an animal model.

About DiaKine --

DiaKine Therapeutics, Inc. is a development-stage company commercializing novel immune modulators initially targeting the treatment of autoimmune and inflammatory diseases such as diabetes and related complications. These new drugs regulate cytokines, part of the body's immune system, which mistakenly attack tissue and cause inflammation. The Company designed its first product, IsletLife-LSF Media 1, to improve the viability and insulin producing capabilities of harvested islet cells prior to transplant. IsletLife-LSF Media thus can potentially improve the success rate of the procedure. Additional therapeutics under development by DiaKine include: adjunct therapy to islet cell transplants, halting the progression of type 1 diabetes in newly diagnosed adults, treatment and prevention of Latent Autoimmune Diabetes of Adults (LADA), treatment and prevention of insulin requiring type 2 diabetic, treatment and prevention of diabetes complications. For more information, visit www.diakine.com.

###END###